Goals/Background: Data on acute variceal hemorrhage (AVH) in the United States is limited and the best method to stratify risk is not clear. Taking advantage of a prospective US cohort study, we aimed to (1) describe clinical outcomes of AVH and their predictors; (2) compare predictors of 6-week mortality. Results: Seventy eligible patient were enrolled; 18 (26%) patients died within 6-weeks of index bleed. Demographic, clinical, and laboratory data were compared between survivors and nonsurvivors. Multivariate models showed that admission CTP or the MELD score (separately) were independent predictors of survival. The discriminative values of CTP (area under receiver operating characteristic: 0.75) and MELD (area under receiver operating characteristic: 0.79) were good and not significantly different (P = 0.27). However, calibration (correlation between observed and predicted mortality) test was significantly better for CTP than for MELD, with the recently described recalibrated MELD model having the worst agreement. Predicted mortality for CTP-A was <10%, CTP-B 10% to 30%; and CTP-C >33%.
in mortality, published series over the past 7 years when current standards of care were established 1, 2 confirm that AVH still carries a 6-week mortality that ranges between 16% and 23%. [3] [4] [5] [6] This variability suggests that cohorts included in these studies belong to different prognostic subgroups. The Child-Turcotte-Pugh (CTP) and the Model for End-Stage Liver Disease (MELD) scores have been identified in several cohort studies as being strongly predictive of outcomes (treatment failure and death) in AVH. 1, 4, 6, 7 In fact, individualized management based on risk stratification by CTP score has already been shown to improve survival in patients with AVH. 8 Although other prognostic models have been developed in patients with AVH, 3, 4, 7, 9 a recent study showed that recalibration of a MELD-based model could accurately predict the risk of death and was superior to other models, including the CTP score. 6 It also identified cutoffs that could be used for risk stratification. Notably, all recent studies were performed in cohorts from outside the United States and contemporary data on mortality of patients with AVH treated with standard therapy (vasoactive drug, antibiotics, and endoscopic band ligation) in the United States are lacking.
A multicenter prospective study of patients with AVH in 15 US centers was performed between August 2006 and April 2008 with the objective of obtaining Food Drug Administration label for vapreotide in the treatment of AVH. Vapreotide, a somatostatin analog akin octreotide, had been previously shown in a placebo-controlled trial to be effective in the treatment of AVH. 10 Patients with AVH were treated with vapreotide, antibiotic prophylaxis, and band ligation as indicated by current guidelines 1,2 and followed prospectively until death or 42 days after enrollment in the study. Taking advantage of available data from this study, we sought to (1) describe the clinical outcomes of a prospective US cohort of patients with AVH treated with current standard of care; (2) determine predictors associated with 6-week mortality and 5-day treatment failure; and (3) compare the ability of CTP, MELD and recalibrated MELD scores in predicting 6-week mortality.
MATERIALS AND METHODS
The vapreotide trial (DEBV-VAP/EVP-301) was a registered observational, open-label, multicenter prospective study using vapreotide in continuous intravenous infusion for 5 days in conjunction with endoscopic band ligation and antibiotics in patients with endoscopically proven AVH. The reason that the study was planned as an open-label study, and not a double-blinded placebo-controlled study, was because the use of octreotide was already recommended in society guidelines and because a well-designed study by Cale`s et al 10 had already shown favorable results with vapreotide compared with placebo. 11 Therefore, it was considered unethical to randomize patients to a placebo. Patients were recruited (ClinicalTrails.gov: NCT00331188) at 15 centers across the United States. With permission from Debiopharm International S.A. (Lausanne, Switzerland) and approval by the institutional review boards from all participating centers, we were provided with the trial database that included deidentified data.
Patients
Patients included in the study were required to have cirrhosis (by biopsy, or a combination of clinical, laboratory, and imaging evidence), an age between 18 and 75 years, presenting with gastrointestinal hemorrhage (hematemesis and/or melena) with an endoscopy (performed within 12 h of presentation) showing that the source of hemorrhage was related to gastroesophageal varices according to Baveno IV criteria. 12 Patients were excluded if they had prior treatment with another vasoactive drug during the active bleeding episode, grade 4 hepatic encephalopathy, balloon tamponade placed at time of admission, CTP score over 13, pregnant or breast-feeding women, known diffuse hepatocellular carcinoma, known complete portal venous thrombosis, had prior variceal bleeding within the last 6 weeks, known allergy to somatostatin or its analogs, prior portosystemic shunt placement [transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt], prior liver transplantation, known cancer, and known chronic kidney disease.
Baseline demographic, history, laboratory, and imaging data were collected at admission. Patients were followed for 42 days or until death. Except for having a placebo arm, this study's protocol was similar to the published vapreotide trial by Cale`s et al. 10 Blood pressure, heart rate, body temperature, any clinical signs of hemorrhage, hemoglobin, hematocrit, number of units of blood, plasma, or substitutes given were recorded at admission, at the end of the initial endoscopy, every 6 hours for the first 48 hours, and then every 12 hours until the end of the 5-day treatment period. Serum glucose, creatinine, aspartate aminotransferase, and alanine aminotransferase, total bilirubin were measured at admission and days 2 and 5 of treatment. Hepatic ultrasound was performed on day 5. Additional patient clinical examinations were performed on days 7, 30, and 42. Adverse events were closely monitored throughout the study period.
Endoscopic and Pharmacologic Therapy
Once enrolled, patients were given vapreotide as an intravenous bolus of 50 mg followed by a continuous infusion of 50 mg/h for 5 days. Infusion was discontinued if endoscopy did not identify the source of bleeding as being related to gastroesophageal varices. Diagnostic and therapeutic endoscopy was performed within 12 hours of admission. Endoscopic band ligation was performed on patients with confirmed esophageal varices. Sclerotherapy was to be used if band ligation was not feasible or was technically difficult. Antibiotic prophylaxis, including either oral norfloxacin or an equivalent fluoroquinolone or intravenous ceftriaxone, was given for at least 5 days. Rescue therapies (balloon tamponade or TIPS) were utilized when there was failure to control bleeding with endoscopy. After 5 days, patients proceeded to have secondary prophylaxis (nonselective beta-blocker plus band ligation in 2-wk intervals).
Outcomes of Interest
In accordance with the more recent Baveno VI consensus conference, 6-week mortality was considered the primary endpoint and 5-day treatment failure, as defined by Baveno IV/V criteria (and as used in the vapreotide trial), was considered a secondary endpoint. 13 In addition to the original objectives of the vapreotide trial, this paper's objectives were to determine predictors of 6-week mortality and to investigate the prognostic performance of CTP in comparison with the recalibrated MELD-based model. 6 All items described in the transparent reporting of a multivariable model for individual prognosis or diagnosis (TRIPOD) statement for studies developing or validation prediction models are reported in the study. 14 
Statistical Analysis
Analyses were performed using intention-to-treat and P-values were 2-tailed. Continuous variables that were not skewed are summarized using means with SD. Continuous variables that tended to be skewed are summarized using medians with interquartile ranges. The 6-week mortality rate was calculated as a percentage of those who died or were lost to follow-up during 6 weeks after the index bleed divided by the total study population size. The 5-day treatment failure rate was calculated as a percentage of those who developed uncontrolled bleeding, early rebleeding, or death within 5 days over the total study population size.
Analysis of Predictors of 6-Week Mortality and 5-Day Treatment Failure
Univariate analysis comparing patients who died or failed therapy at 6 weeks versus those who did not was performed using the student t test or w 2 test. Multivariable models were developed with the objective of validating the prognostic value of MELD versus CTP score using covariates that were statistically significant on univariate analysis. Because of the relatively small number of outcomes, a maximum of 2 covariates, outside of CTP or MELD, were used to control the models. Variables that were components of scores (CTP or MELD) were not included in the models.
Analysis of Prognostic Ability of CTP, MELD, and Recalibrated MELD Scores
To investigate the discriminative ability of the prognostic models for 6-week mortality, receiver operating characteristic curve analyses were performed. The Hosmer-Lemeshow goodness-of-fit test was used to determine the models' calibration (the agreement between the observed and predicted risk of mortality) after splitting the sample into deciles (ie, Data are expressed as medians (first interquartile, third interquartile) or n (%) unless otherwise stated.
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HR, heart rate; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; SBP, systolic blood pressure; TIPS, transjugular intrahepatic portosystemic shunt.
groups of 10 patients each). If the specified model were to provide an adequate fit and model prediction was not different from observed values, then the null hypothesis could not be rejected (higher P-value means nonsignificant disagreement). However, evidence of poor agreement between observed and predicted risk of mortality would yield a smaller P-value (ie, significant disagreement). Calibration was also performed for the recently described MELD-based model in patients with AVH. 6 Analyses were performed using SAS version 9.3 (SAS Inc., Cary, NC) software.
RESULTS

Description of Cohort
A total of 103 patients with cirrhosis were admitted to 15 US centers with upper gastrointestinal bleeding in the period between August 2006 and April 2008 and were initiated on vapreotide infusion before diagnostic endoscopy. Thirty-three patients were excluded and the causes for exclusion are specified in Figure 1 . Therefore, the final intention-to-treat analysis included 70 patients who had endoscopically proven variceal hemorrhage. Baseline characteristics of these patients are shown in Table 1 . Eighteen (26%) patients died within 6 weeks of index hemorrhage, including 7 (10%) that died within the first 5 days. Only 1 patient died from uncontrolled bleeding (occurring after 5 d from index bleed) while the remaining deaths were related to either liver failure or multiorgan failure. Five-day treatment failure occurred in 16 (23%) of the 70 patients. Among those 16, 12 (17%) patients had uncontrolled bleeding within the first 48 hours of the index bleed and 4 (6%) had early rebleeding (occurring between days 2 and 5).
Predictors of 6-Week Mortality
Univariate analyses comparing 6-week survivors versus nonsurvivors are shown in Table 2 . As expected, Child score and MELD score were significantly different between groups, with a median Child score of 8 among survivors (compared with 10 among nonsurvivors) and a median MELD score of 13 among survivors (compared with 21 in nonsurvivors). Because ascites and albumin are part of the CTP score and INR and creatinine are part of the MELD score, they were not included in the multivariable model. We did not include prior variceal hemorrhage because of the small number of deaths in this category which would result in instability in the estimation of the coefficient for this covariate. Therefore, our multivariable model for 6-week mortality included only 3 covariates: the independent effects of either MELD or CTP score and potential confounders of prior prophylaxis and baseline hemoglobin. None of the models included both CTP and MELD scores because these 2 variables were highly correlated (r = 0.72, P < 0.001). Only CTP (P = 0.01) and MELD (P = 0.004) remained as independent significant predictors of 6-week mortality (Supplementary Table 1 
Predictors of 5-Day Treatment Failure
Univariate analyses comparing 5-day treatment failures versus those who did not fail therapy are shown in Table 3 . Because albumin is part of the CTP score and creatinine is part of the MELD score, they were not included in the multivariable model. Therefore, our multivariable model for 5-day treatment failure included only 3 covariates: the independent effects of either MELD or CTP score and potential confounders of age and baseline hemoglobin. Only CTP (P = 0.03) and MELD (P = 0.02) remained as independent significant predictors of 5-day treatment failure (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww.com/JCG/A287).
Comparison of the Ability of CTP, MELD, and Recalibrated MELD in the Prediction of 6-Week Mortality
Given that CTP and MELD score were both found to be independent predictors of 6-week mortality, comparisons on their prognostic capabilities (discrimination and calibration) were performed using the original CTP and MELD scores from our cohort. Area under the receiver operating characteristic (AUROC) analyses were used to measure the discriminative ability (ie, distinguishing the risk of dying vs. not dying) between both scores (Fig. 2) . Although the AUROC for MELD score (AUROC: 0.79; 95% confidence interval, 0.68-0.90) was greater than for the CTP score (AUROC: 0.75; 95% confidence interval, 0.63-0.87), the difference was not statistically significant (P = 0.27). Calibration plots for the CTP, MELD, and MELDbased model developed by Reverter are shown in Figure 3 . Agreement between observed and predicted risk of 6-week mortality was best for the CTP score (P = 0.45, ie, there was no significant disagreement between observed and predicted), intermediate for the MELD score (P = 0.02, ie, a significant disagreement between observed and predicted) and worst for the MELD-based model developed by Reverter (P = 0.0006, ie, a very significant disagreement between observed and predicted). Table 4 shows the predicted risk of 6-week mortality for every CTP score. Child CTP class A (scores 5 to 6) has a predicted mortality of <10%, class B (scores 7 to 9) a mortality risk between 10% and 30% and class C (scores 10 to 13) was associated with a risk >33%. Using data from our cohort, a fitted model for CTP score was developed: logit = À5.5125 + 0.4865 ÂCTP score.
DISCUSSION
This study presents clinical outcomes after AVH using a contemporary prospective multicenter cohort from the United States. Per recent Baveno consensus recommendations, we specifically looked at 6-week mortality as the primary outcome as well as looked at predictors of death to further refine risk stratification. 13 Compared with recent (mid-2000s or later) prospective cohort (nonrandomized) studies enrolling patients with cirrhosis of all severities, our 6-week mortality rate of 26% is comparable with that of Amitrano et al 5 (23%) but higher than that of Reverter et al 6 (16%) which could be explained given a higher proportion of CTP class C patients in our cohort (36% vs. 28% in the Reverter cohort). The Amitrano and colleagues study had an even lower proportion of CTP class C patients (20%) but included patients with hepatocellular carcinoma and portal vein thrombosis, complications that were not present in our or Reverter's cohorts and that could carry a higher mortality. Both these recent studies were single center studies while our cohort was a 15-center study. Compared with an older US multicenter cohort, 3 our 6-week mortality was higher (26% vs. 19%) but the study does not specify the proportion of CTP class C patients so the severity of liver disease cannot be adequately assessed, although a higher MELD score in our cohort (14.5 vs. 12) suggests a sicker patient population. Compared with the original randomized controlled trial by Cale`s et al, 10 the mortality in the present study was higher (26%) than in their vapreotide arm (14%) despite the fact that Child class distribution was comparable between studies. However, the etiology of cirrhosis was different; while in the Cale`s study 84% of patients had alcoholic cirrhosis, this was only present in 43% of patients in the present study. Because nonalcoholic cirrhosis has been shown to be an independent risk factor for treatment failure and death, this factor could explain survival differences between the studies. 9 Therefore, a somewhat higher mortality in our cohort may be explained on the basis of a greater severity of cirrhosis. Our cohort was collected before the "early" TIPS study had been published. 8 This study was the first to demonstrate that survival could be improved in patients at a higher risk of failing standard therapy (antibiotics, vasopressors, endoscopic ligation) by pre-empting failure with TIPS placement (that had previously been reserved for patients who failed standard therapy). These were patients with CTP scores 10 to 13 or CTP B patients (score 7 to 9) with active variceal hemorrhage on diagnostic endoscopy. In our cohort, the failure and mortality rates of patients meeting these criteria were 26% and 32%, respectively, and were higher than those who did not meet these criteria, 8% and 0%, respectively.
The pre-emptive TIPS study has opened the way to proper risk stratification of patients with AVH and thereby demand the need to better stratify. In fact, the Baveno consensus suggested the need for improved risk stratification for this particular patient population. 13 Clearly, not all patients carry the same risk of treatment failure and death. Several studies have investigated prognostic models on their prediction for adverse outcomes after AVH. 1, 3, 4, 6, 7, 9 One particularly strong prognosticator is the measurement of the hepatic venous pressure gradient Z20 mm Hg within 24 hours of the bleeding episode, but this strategy is not universally accessible, especially in the United States. 9 Nonetheless, accurate risk stratification based on prognostic models will allow for better individualized management of AVH.
Recently, Reverter et al 6 used a Spanish cohort and developed a MELD-based model to provide defined cutoffs that accurately predict low and high mortality risk specifically after AVH. One advantage from this study included the ability to report the risk of dying from AVH for each MELD score, and thus allowed providers the ability to counsel patients and their families. Yet, the use of just 3 CTP classes provide clinicians easy-to-use risk stratification and may carry an advantage over MELD in that CTP also accounts for known important prognostic factors (ie, ascites and encephalopathy). Ascites has consistently been shown to improve mortality risk prediction in patients who have low MELD scores. 15, 16 The present study confirms that the 2 best predictors of death (and failure of standard therapy) are in fact the CTP and MELD scores. We could, however, not confirm the agreement between predicted and actual risk of death using the recalibrated MELD score and showed that this agreement was better with the CTP score. Although the CTP score provides less granularity regarding individual risk (with a score ranging from 5 to 15, it provides 11 "risk" points) than the MELD score (with a score ranging from 6 to >30, it provides 25 risk points), it would provide a more reliable way to stratify patients into 3 risk strata; thus, allowing further investigation into different treatment regimens for each risk group-providing less intense therapy to those with lower risk of dying and more intense therapy to those with higher risk of dying. This strategy can be already appreciated in the pre-emptive TIPS study described above 8 as well as a recent analysis of antibiotic use in patients with cirrhosis and variceal hemorrhage that showed that CTP class A patients may derive no benefit from antibiotic prophylaxis and showed that MELD scores were not as useful in classifying patients at risk for infection as the CTP class. 17 On the basis of our results, we have provided a fitted Child-Pugh score model that could be validated and even recalibrated in future cohorts with a larger number of patients/outcomes.
This study therefore describes a relatively recent prospective cohort study of patients with AVH across the United States using current standards of care and shows that the patients with AVH may be presenting at more advanced stages of cirrhosis. It also demonstrates that our current practice of stratifying patients using the CTP class is sound and should be used both clinically and in research.
